Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.Мечникова» Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41; 2Многопрофильная клиника «Скандинавия». 191014, Россия, Санкт-Петербург, Литейный пр-т, д. 55А; 3ФГБОУ ВО «Санкт-Петербургский государственный университет». 199034, Санкт-Петербург, Университетская наб. д. 7/9
Список исп. литературыСкрыть список 1. Vovin RJ, Aksenova IO. Chronic depressions. Leningrad, 1982. 2. Krasnov VN. The patterns of depression dynamics: clinical, pathogenetic and therapeutic aspects. Depression and comorbid disorders. Edited by АB Smulevich. Мoscow: RAMS, 1997; p. 80–97. 3. Mosolov SI. The fundamentals of psychopharmacotherapy. Мoscow, 1996; p. 288. 4. Neduva АА, Malin DI, Kostitsyn NV. The experience and prospects of use of some new drugs for treating atypical and complicated depressions. Soc Clin Psychiatry 1996; 2: 99–105. 5. Hamilton M. A rating scale for depression. J Neurology Neurosurg Psychiatry 1960; 12: 56–62. 6. Franken I, Rassin E, Muris P. The assessment of anhedonia in clinical and non-clinical populations: Further validation of the Snaith–Hamilton Pleasure Scale (SHAPS). J Affect Disord 2007; 99: 83–9. 7. Nakonezny P, Carmody T, Morris D et al. Snaith–Hamilton Pleasure Scale, Psychometric evaluation of the Snaith–Hamilton Pleasure Scale (SHAPS) in adult outpatients with major depressive disorder. Int Clin Psychopharmacol 2010; 25 (6): 328–33. 8. Yadov VA. The strategy of social research. The description, interpretation and comprehension of social reality. Moscow, 2007. 9. Kanner AM, Barryb JJ. The impact of mood disorders in neurological diseases: should neurologists be concerned? Epilepsy Behav 2003; 4: 3–13. 10. Smulevich AB. Depression in general practice. Мoscow, 2001. 11. Smulevich AB. Depression with underlying physical and mental disorders. Мoscow, 2003. 12. Smulevich AB. Mental disorders in clinical practice. Мoscow, 2011. 13. Reshetova Т, Reshetov А. Psychosocial changes in the mental health of modern society and cognitive-saving therapy. 19 International conference Association of Psychology and Psychiatry for Adults and Children. Athens, 2014; p. 30. 14. Reshetova TV, Kiseleva ЕО, Gerasimova АV, Nikitina VV. Cognitive disorders in general practice: diagnostics and treatment. The collection of abstracts of 14th Conference "The Program "Psycosomatic medicine". Saint Petersburg, 2014; p. 14. 15. Ballmaier M, Toga AW, Blanton RE. Anterior cingulate, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patients: an MRI-based parcellation of the prefrontal cortex. Am J Psychiatry 2004; 161 (1): 99–108. 16. Bremner JD, Vythilingam M, Vermetten E. Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 2002; 51 (4): 273. 17. Taylor WD, McFall JR, Payne ME. Late-life depression and microstructural abnormalities in dorsolateral prefrontal cortex white matter. Am J Psychiatry 2004; 161 (7): 1293. 18. Pozdeeva Е.А. The neuroplasticity-based hypothesis of affective disorders. A new approach to depression therapy. Psychiatry and Psychopharmacotherapy. 2007; 9 (1): 49–58. 19. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. J Psychiatry 2004; 161 (11): 1957. 20. Campbell St, Marriott M, Nahmias C. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004; 161: 598–607. 21. Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 1998; 9: 2023. 22. Gunten A, Fox NC, Cipolotti L, Ron MA. A volumetric study of hippocampus and amygdala in depressed patients with subjective memory problems. J Neuropsychiatry Clin Neurosci 2000; 12: 493. 23. Hamidi M, Drevets WC, Price JL. Glial reduction in amygdale in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 2004; 55: 563. 24. Jacobsen JSt, Reinhart P, Pangalos MN. Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer′s disease. J Am Soc Exp Neuro Therapeut 2005; 2: 612. 25. Taylor WD, McFall JR, Payne ME. Greater MRI lesion volumes in elderly depressed subjects than in control subjects. Psychiatry Res 2005; 139: 7. 26. Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport 1998; 9: 28. 27. Rajkowska G, Miguel-Hidalgo JJ, Wei J. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45: 98. 28. Topolyansky VD, Strukovskaya MV. Psychosomatic disorders. Мoscow, 1986. 29. Desyatnikov VF, Sorokina ТТ. Latent depression in medical practice. Minsk, 1981; p. 240. 30. Aglitis IR. Senestopathies. Moscow, 1977. 31. Maso GE, Neznanov NG. Treatment resistant depressions. Saint Petersburg, 2013. 32. Reshetova TV. Loss syndrome in general practice and its treatment. New Saint Petersburg Medical News. 2005; 3: 34–8. 33. Reshetova TV, Reshetov AV, Troik ЕB, Gerasimova АV. Medico-social causes of insomnia and its treatment. URL: http://www. remedium.ru/pda/drugs/detail.php?ID=62466 (date 12.01.2015) 34. Fossati P, Jabourian M, Laredo J. Early effects of agomelatine on self-referential processing in acute depressed patients: a fMRI study. Poster presented at 21th European Congress of Psychiatry, Nice (France), April 2013. Paris, 2013; p. 56. 35. Chronobiological theory of affective disorders. Edited by SN Mosolov. Мoscow, 2014. 36. Reshetova TV, Zhigalova TN, Gerasimova АV, Petrenko VA. The treatment of co-occurring anxiety disorders in patients with colonopathy. Gastroenterology 2013; 3–4: 25–30. 37. Montgomery SA. Pregabalin in generalized anxiety disorder therapy (detailed abstract). Ment Disord Gen Pract 2010; 1: 3–6. 38. Levine I. Sleep and Behaviour. 3rd International Meeting on sleep disorders, April 17–18. Bordeaux, 1997; p. 40–1. 39. Swift CG. Disorders, quality of life and use of gipnotik agents. Sleep Disoders and Insomnia in the Elderly. Facts Res Gerontol 1993; 2: 165–75. 40. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 2004; 58: 720–40. 41. Kasper S, Hamon M. Agomelatine, a new antidepressant with an innovative mechanism of action – an overview on its preclinical and clinical development program. World J Biol Psychiatry 2009; 10–11: 126. 42. Audinot V, Mailliet F, Lahaye-Brasseur C. New selective ligands of human clonedmelatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 2003; 367: 553–61. 43. Rainer Q, Xia L, Guilloux JP et al. Beneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety. Int J Neuropsychopharmacol 2011; 1: 15. 44. Montgomery SA, Kennedy SH, Burrows GD et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271–80. 45. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007; 10: 661–73. 46. Montgomery SA, Baldwin DS, Blier P et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007; 22: 323–29. 47. Kasper S, Hajak G, Wulff K et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle, depressive and anxiety symptoms in patients with Major Depressive Disorder. A randomized, double-blind comparison with sertraline. J Clin Psychiatry 2010; 71: 109–20. 48. Loo H, Hale A, D′Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239–47. 49. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Pharmacol 2004; 58: 720–40. 50. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry 2007; 68: 1723–32. 51. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93–100. 52. Martinotti G, Sepede G, Gambi F. Agomelatine Versus Venlafaxine XR in the Treatment of Anhedonia in Major Depressive Disorder. A Pilot Study. J Clin Psychopharmacol 2012; 32 (4): 487–91. 53. Fossati P. Imaging autobiographical memory. Dialogues Clin Neurosci 2013; 15 (4): 487–90. 54. Price J. Emotional side effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry 2009; 195 (3): 211–7. 55. Nutt D, Demyttenaere K, Janka Z et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2007; 21 (5): 461–71. 56. Di Giannantonio M, Di Iorio G, Guglielmo R. Major depressive disorder, anhedonia. J Biol Regul Homeost Agents 2011; 25: 109–14. 57. Medvedev VE, Gaushanskaya EV, Israelyan AY. The therapy of depressions with anhedonia (Valdoksan experiment). Psychiatry and Psychopharmacotherapy 2014; 16 (3): 45–9. 58. Medvedev VE. The therapy of non-psychotic depressions as part of involutional hysteria (Valdoksan experiment). Psychiatry and Psychopharmacotherapy 2011; 13 (4): 14–8. 59. Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci 2012; 35 (1): 24–5. 60. Light SN, Heller AS, Johnstone T. Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder. Biol Psychiatry 2011; 70: 962. 61. Harvey PO, Fossati P, Lepage M. Modulation of Memory Formation by Stimulus Content: Specific Role of the Medial Prefrontal Cortex in the Successful Encoding of Social Pictures. J Cogn Neurosci 2007; 19 (2): 351–62. 62. Millet B, Jaafari N, Polosan M et al. Limbic versus cognitive target for deep brain stimulation in treatment-resistant depression: accumbens more promising than caudate. Eur Neuropsychopharmacol 2014; 24 (8): 39. 63. Hasler BР. Phase relationships between core body temperature, melatonin, and sleep are associated with depression severity: further evidence for circadian misalign mention-seasonal depression. Psychiatry Res 2010; 178: 205–7. 64. Quera Salva MA, Hajak G, Philip P et al. Comparative effects of agomelatine and escitalopram in sleep in MDD patients. Int Clin Psychopharmacol 2011; 26: 252–62. 65. Zisapel N. Circadian rhythm sleep disorders: pathophysiology and potential approaches to management. CNS Drugs J 2001; 15 (4): 311–28. 66. Szabadi E. Drugs for sleep disorders: mechanisms and therapeutic prospects. Br J Clin Pharmacol 2006; 61: 761–6. 67. Kovalson VM. Melatonin without wonders. Man and His Health 2003; 37: 23–7. 68. Arendt J, Skene DJ, Middleton B et al. Efficacy of melatonin treatment in jet lag, shift work, and blindness. J Biol Rhythms 1997; 12: 604–17. 69. Waldhauser F Weiszenbacher G, Tatzer E. Alterations in nocturnal serum melatonin levels in humans with growth and aging. J Clin Endocrinol Metab 1988; 66: 648–52. 70. Zaslavskaya RM, Shakirova АN, Lilitsa АG, Sherban EА. Melatonin in combination therapy for patients with cardiovascular diseases. Мoscow, 2005. 71. Leproult R, van Onderbergen A, L′Hermite-Baleriaux M et al. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf) 2001; 63: 298–304. 72. Souetre E, Salvati E, Belugou JL et al. Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res 1989; 28: 263–78. 73. Millan MJ, Gobert A, Lejeune F. The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways. J Pharmacol Exp Ther 2003; 306: 954–64.